Krysiak Robert, Okopień Bogusław
Slaski Uniwersytet Medyczny, Klinika Chorób Wewnetrznych i Farmakologii Klinicznej, Katedry Farmakologii.
Pol Merkur Lekarski. 2007 Aug;23(134):145-50.
Parathyroid carcinoma is a rare endocrine tumour accounting for only about one of every hundred cases of primary hyperparathyroidism. The aetiology of this cancer remains obscure but the recent studies have identified that some gene mutations may be involved in its pathogenesis. Most patients with parathyroid carcinoma suffer from symptoms related to marked hypercalcemia; the incidence of associated renal, bone, gastrointestinal, neuromuscular and psychological symptoms is much more frequent than in those with benign parathyroid adenomas. The course of patients with parathyroid carcinoma is variable. However, in more than 50% cases, patients experience persistent or recurrent disease due to regional or distant disease. The treatment of parathyroid malignancy is predominantly surgical, comprising an initial en bloc resection of the tumour and adjacent neck structures. Several studies have suggested the usefulness of pharmacotherapy in the palliative treatment of the debilitating symptoms of hypercalcemia. The aim of this paper is to summarise the present state of knowledge on the aetiology, clinical presentation, diagnosis and treatment of parathyroid carcinoma.
甲状旁腺癌是一种罕见的内分泌肿瘤，仅占原发性甲状旁腺功能亢进症病例的约百分之一。这种癌症的病因尚不清楚，但最近的研究发现一些基因突变可能参与其发病机制。大多数甲状旁腺癌患者患有与明显高钙血症相关的症状；与良性甲状旁腺腺瘤患者相比，相关的肾脏、骨骼、胃肠道、神经肌肉和心理症状的发生率要高得多。甲状旁腺癌患者的病程各不相同。然而，在超过50%的病例中，患者由于局部或远处疾病而经历持续性或复发性疾病。甲状旁腺恶性肿瘤的治疗主要是手术治疗，包括最初整块切除肿瘤及相邻的颈部结构。几项研究表明药物治疗在缓解高钙血症所致虚弱症状的姑息治疗中有用。本文的目的是总结甲状旁腺癌病因、临床表现、诊断和治疗的现有知识状况。
